David R Epstein
CIK 1445826 · CEO · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.50M
Companies
9
Total Filings
95
Lifetime Open-Market Net
-$3.40M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TEM | Director | 31,464 | $47.82 | $1.50M | -$278.0K | 16 | 2026-06-03 |
| Seagen Inc. (SGEN) Delisted | CEO | 0 | $228.74 | $0 | -$2.26M | 4 | 2023-12-15 |
| SNTI | Director | — | $0.96 | — | $0 | 1 | 2022-07-15 |
| EVLO | Director | 93,932 | $0.00 | $9 | $120.7K | 19 | 2022-06-30 |
| Axcella Health Inc. (AXLA) Delisted | Director | 209,756 | $0.40 | $84.1K | $786.7K | 29 | 2022-06-03 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | Director | 4,720,012 | $0.08 | $391.8K | -$1.77M | 10 | 2022-05-13 |
| INTERNATIONAL FLAVORS & FRAGRANCES INC (IFFT) Delisted | Director | — | $47.56 | — | $0 | 5 | 2020-11-04 |
| IFF | Director | — | $78.27 | — | $0 | 9 | 2018-05-03 |
| Molecular Insight Pharmaceuticals, Inc. (MIPI) Delisted | Director | — | — | — | $0 | 1 | 2008-09-24 |
Recent Filings · Page 3 of 10
95 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-07-15 | SNTI | Grant (A) | — | $0 | EDGAR |
| 2022-06-30 | EVLO | Exer (M) | +4,927 | $0 | EDGAR |
| 2022-06-13 | EVLO | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | — | Mixed | +112,519 | $0 | |
| 2022-06-03 | Axcella Health Inc. (AXLA) Delisted | Grant (A) | +47,059 | $0 | EDGAR |
| 2022-06-01 | EVLO | Exer (M) | +4,925 | $0 | EDGAR |
| 2022-05-31 | EVLO | Buy (P) | +17,123 | $25.0K | EDGAR |
| 2022-05-13 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-02 | EVLO | Exer (M) | +4,926 | $0 | EDGAR |
| 2022-04-22 | Rubius Therapeutics, Inc. (RUBY) Delisted | Buy (P) | +30,000 | $43.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.